SeaStar Medical: Steady Progress in Pediatric AKI and Pivotal Trial Enrollment, Yet Market Remains Unimpressed
Q1 revenue up 69%, trial on track, but stock continues slide
ICU · Earnings Call · 2026-05-13
Early-Stage Commercial and Clinical Momentum
SeaStar Medical reported first-quarter 2026 results that highlighted continued progress in its commercial launch and pivotal clinical program. QUELIMMUNE net revenue reached $495,000, a 69% increase year-over-year, driven by the addition of seven new hospitals in the quarter. As CEO Eric Schlorff noted, “The increase in our QUELIMMUNE customer base has helped propel our first quarter QUELIMMUNE net revenue with a nearly 70% increase from the first quarter of 2025.” — Eric Schlorff, Chief Executive Officer · 2026-05-13 The company now has 17 active customers, well on its way to the goal of 15 new customers for the full year. This momentum in pediatric AKI establishes a foundation for what management repeatedly frames as the much larger adult market opportunity.Clinical Pipeline and Regulatory Engagement
The central value driver remains the NEUTRALIZE AKI pivotal trial. Enrollment reached 198 of 339 patients, up from 146 in the prior update (as Kevin Chung had stated in the November call: “We are currently at 146 patients enrolled. We have 17 sites activated.” — Kevin Chung, Chief Medical Officer · 2025-11-13), with UCLA added as a site. Management continues to target completion by year-end and anticipates top-line results in mid-2027. Kevin Chung emphasized the regulatory strategy: “We are already working with the FDA on our plans to submit a modular PMA, enabling us to complete most of the submission with the exception of pivotal data.” — Kevin Chung, Chief Medical Officer · 2026-05-13 This approach, combined with the company's breakthrough device designations, could accelerate approval. The completion of the SAVE Registry at 50 patients and the request to transition it to a voluntary study adds another potential catalyst, reducing administrative burden for hospitals and supporting adoption.Financial Position and Market Reality
Financial discipline remains intact. Operating expenses were flat at $4.1 million, and gross margin exceeded 90%. Net loss narrowed to $3.5 million, and cash stood at $9.3 million. However, with a cash runway of only 3.4 quarters, the company will likely need to raise additional capital before the adult trial reads out. Despite the operational progress, the stock has continued to slide, down ~34% from its July peak and off ~10% over the past 90 days. The full price tape shows a -99.9% decline from the 2022 peak, reflecting extreme dilution and persistent losses.The conference call did not introduce any major new strategic pivots, but the steady execution on enrollment and commercial adoption underlines the potential. The market, however, remains deeply skeptical, as reflected in the SCD therapy stock price. For investors, the key question is whether the upcoming data readouts and FDA interactions can re-rate the story. Interestingly, the company's revenue guidance for the year (~$2M) and the past target of "a million plus this year" (as Eric Schlorff noted in the prior call: “we were on target to do a million plus this year.” — Eric Schlorff, Chief Executive Officer · 2025-11-13) shows consistent, if modest, growth.The SCD's unique immunomodulatory mechanism positions us to potentially reshape treatment paradigms across a range of serious conditions, not only for AKI, but cardiorenal syndrome and other states of pathologic immune activation.